Critical Appraisal of the 2018 ACC Scientific Sessions Late-Breaking Trials From a Statistician's Perspective

Journal of the American College of Cardiology

Volumn 71, Issue 25, 2018, Pages 2957-2969

  Pocock, Stuart J ^a   Collier, Tim J ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

clinical trials; conference presentations; critical appraisal

Indexed keywords

ALIROCUMAB; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CLOPIDOGREL; METOPROLOL; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TICAGRELOR;

ACUTE CORONARY SYNDROME; BLEEDING; CARDIOLOGY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; DUAL ANTIPLATELET THERAPY; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LOADING DRUG DOSE; MEDICAL LITERATURE; NAMED GROUPS BY OCCUPATION; NONMEDICAL OCCUPATIONS; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STATISTICIAN; STENT THROMBOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS; STATISTICS AND NUMERICAL DATA; TRENDS;

CARDIOLOGY; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STATISTICS AS TOPIC;

EID: 85046622487     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.04.015     Document Type: Review

References (32)

1. Boutron, I., Altman, D.G., Hopewell, S., Vera-Badillo, F., Tannock, I., Ravaud, P., Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial. J Clin Oncol 32 (2014), 4120–4126.
2. Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY Outcomes trial. Am Heart J 2014;168:682–9.e1.
3. Pocock, S.J., Lubsen, J., More on subgroup analyses in clinical trials. N Engl J Med 358 (2008), 2076–2077.
4. Food and Drug Administration. Multiple Endpoints in Clinical Trials: Guidance for Industry. 2017, Food and Drug Administration, College Park, Maryland.
5. Assmann, S.F., Pocock, S.J., Enos, L.E., Kasten, L.E., Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 355 (2000), 1064–1069.
6. Wang, R., Lagakos, S.W., Ware, J.H., Hunter, D.J., Drazen, J.M., Statistics in medicine—reporting of subgroup analyses in clinical trials. N Engl J Med 357 (2007), 2189–2194.
7. Sabatine, M.S., Giugliano, R.P., Keech, A.C., et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376 (2017), 1713–1722.
8. ClinicalTrials.gov. Vest Prevention of Early Sudden Death Trial and VEST Registry (VEST). October 5, 2011. Available at: http://clinicaltrials.gov/ct/show/NCT01446965?order=1. Accessed March 23, 2018.
9. Pocock, S.J., Clayton, T.C., Stone, G.W., Challenging issues in clinical trial design: part 4 of a 4-part series on statistics for clinical trials. J Am Coll Cardiol 66 (2015), 2886–2898.
10. Berwanger, O., Santucci, E., de Barros e Silva, P., et al. Effect of loading dose of atorvastatin prior to planned percutaneous coronary intervention on major adverse cardiovascular events in acute coronary syndrome: the SECURE-PCI randomized clinical trial. JAMA 319 (2018), 1331–1340.
11. Pocock, S.J., Stone, G.W., The primary outcome fails—what next?. N Engl J Med 375 (2016), 861–870.
12. Hirji, K.F., Fagerland, M.W., Outcome based subgroup analysis: a neglected concern. Trials, 10, 2009, 33.
13. Yusuf, S., Wittes, J., Probstfield, J., Tyroler, H.A., Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 266 (1991), 93–98.
14. TREAT Study Group. Ticagrelor vs clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a randomized clinical trial. JAMA Cardiol 3 (2018), 391–399.
15. Lüscher, T.F., Gersh, B., Landmesser, U., Ruschitzka, F., Is the panic about beta-blockers in perioperative care justified?. Eur Heart J 35 (2014), 2442–2444.
16. Kristensen, S.D., Knuuti, J., Saraste, A., et al. 2014 ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management. Eur Heart J 35 (2014), 2383–2431.
17. POISE Study Group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008;371:1839–47.
18. Giustino, G., Baber, U., Sartori, S., et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 65 (2015), 1298–1310.
19. Hahn, J.-Y., Song, Y.B., Oh, J.-H., et al., for the SMART-DATE Investigators. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet 391 (2018), 1274–1284.
20. Macaya, F., Ryan, N., Salinas, P., Pocock, S.J., Challenges in the design and interpretation of noninferiority trials: insights from recent stent trials. J Am Coll Cardiol 70 (2017), 894–903.
21. Kosiborod, M., Lam, C.S.P., Kohsaka, S., et al. Lower cardiovascular risk associated with SGLT-2i in >400,000 patients: the CVD-REAL 2 study. J Am Coll Cardiol, 2018 Mar 11 [E-pub ahead of print].
22. Brown, M.L., Gersh, B.J., Holmes, D.R., Bailey, K.R., Sundt, T.M. 3rd, From randomized trials to registry studies: translating data into clinical information. Nat Clin Pract Cardiovasc Med 5 (2008), 613–620.
23. Freemantle, N., Marston, L., Walters, K., Wood, J., Reynolds, M.R., Petersen, I., Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research. BMJ, 347, 2013, f6409.
24. Pocock, S.J., Elbourne, D.R., Randomized trials or observational tribulations?. N Engl J Med 342 (2000), 1907–1909.
25. Kosiborod, M., Cavender, M.A., Fu, A.Z., et al. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study. Circulation 136 (2017), 249–259.
26. Borenstein, M., Hedges, L.V., Higgins, J.P.T., Rothstein, H.R., Introduction to Meta-Analysis. 2009, Wiley, Chichester, West Sussex, United Kingdom.
27. Poole, C., Greenland, S., Random-effects meta-analyses are not always conservative. Am J Epidemiol 150 (1999), 469–475.
28. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
29. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
30. ClinicalTrials.gov. Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58). November 21, 2012. Available at: http://clinicaltrials.gov/ct/show/NCT01730534?order=1. Accessed March 23, 2018.
31. Raz, I., Mosenzon, O., Bonaca, M.P., et al. DECLARE-TIMI 58: participants’ baseline characteristics. Diabetes Obes Metab 20 (2018), 1102–1110.
32. Moher, D., Hopewell, S., Schulz, K.F., et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ, 340, 2010, c869.